Long-Term Survival and Apolipoprotein A1 Level in Chronic Heart Failure: Interaction With Tumor Necrosis Factor α-308 G/A Polymorphism

Tímea Gombos, Zsolt Förhécz, Zoltán Pozsonyi, Lívia Jánoskuti, Z. Prohászka, I. Karádi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Apolipoprotein A1 (ApoA1), a major constituent of high-density lipoprotein (HDL), has antiinflammatory and antioxidative properties and plays a prognostic role in chronic heart failure (CHF). Despite increased tumor necrosis factor α (TNFα) levels being linked to worse outcome of HF, the results are ambiguous about the association of functionally active 308 promoter polymorphism of the TNFα gene. The aims of our study were to investigate the association of ApoA1 and TNFα levels with mortality and to evaluate potential interaction between these factors and TNFα-308 polymorphism. Methods: Together with several parameters ApoA1, TNFα levels and TNFα-308 polymorphism were determined in a cohort of 195 patients with CHF who were followed for 5 years. Results: Low ApoA1 and high TNFα levels were associated with more severe disease, and ApoA1 showed the strongest relationship with HDL, total cholesterol, C-reactive protein, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). TNFα-308 A carriers had significantly higher ApoA1 levels than wild-type (GG) patients (1.41 ± 0.268 vs 1.29 ± 0.324 g/L; . P = .007), whereas levels of TNFα were the same in these groups. Decreased ApoA1 levels were significant predictors of 5-year mortality (NT-proBNP-adjusted HR for 1 decile decrease in ApoA1 level was 1.10 (P = .011). Interaction was found between the ApoA1 level and TNFα-308 polymorphism, because in patients with GG haplotype the adverse effect of low ApoA1 level on survival was more prevalent. Conclusions: Lower ApoA1 levels were strongly associated with adverse outcome in CHF patients in a TNFα-308 polymorphism dependent manner. These observations support the complex involvement of malnutrition and inflammation in the pathogenesis of CHF.

Original languageEnglish
JournalJournal of Cardiac Failure
DOIs
Publication statusAccepted/In press - Dec 10 2015

Fingerprint

Apolipoproteins
Apolipoprotein A-I
Heart Failure
Tumor Necrosis Factor-alpha
Survival
Brain Natriuretic Peptide
Mortality
HDL Lipoproteins
Malnutrition
C-Reactive Protein
Haplotypes
HDL Cholesterol
Anti-Inflammatory Agents
Inflammation

Keywords

  • Apolipoprotein A1 (ApoA1)
  • Cholesterol paradox
  • Chronic heart failure (CHF)
  • TNFα-308 G/A promoter polymorphisms
  • Tumor necrosis factor alpha (TNFα)

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Long-Term Survival and Apolipoprotein A1 Level in Chronic Heart Failure : Interaction With Tumor Necrosis Factor α-308 G/A Polymorphism. / Gombos, Tímea; Förhécz, Zsolt; Pozsonyi, Zoltán; Jánoskuti, Lívia; Prohászka, Z.; Karádi, I.

In: Journal of Cardiac Failure, 10.12.2015.

Research output: Contribution to journalArticle

@article{9318ed4735af4c97ad398d07b1d1933b,
title = "Long-Term Survival and Apolipoprotein A1 Level in Chronic Heart Failure: Interaction With Tumor Necrosis Factor α-308 G/A Polymorphism",
abstract = "Background: Apolipoprotein A1 (ApoA1), a major constituent of high-density lipoprotein (HDL), has antiinflammatory and antioxidative properties and plays a prognostic role in chronic heart failure (CHF). Despite increased tumor necrosis factor α (TNFα) levels being linked to worse outcome of HF, the results are ambiguous about the association of functionally active 308 promoter polymorphism of the TNFα gene. The aims of our study were to investigate the association of ApoA1 and TNFα levels with mortality and to evaluate potential interaction between these factors and TNFα-308 polymorphism. Methods: Together with several parameters ApoA1, TNFα levels and TNFα-308 polymorphism were determined in a cohort of 195 patients with CHF who were followed for 5 years. Results: Low ApoA1 and high TNFα levels were associated with more severe disease, and ApoA1 showed the strongest relationship with HDL, total cholesterol, C-reactive protein, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). TNFα-308 A carriers had significantly higher ApoA1 levels than wild-type (GG) patients (1.41 ± 0.268 vs 1.29 ± 0.324 g/L; . P = .007), whereas levels of TNFα were the same in these groups. Decreased ApoA1 levels were significant predictors of 5-year mortality (NT-proBNP-adjusted HR for 1 decile decrease in ApoA1 level was 1.10 (P = .011). Interaction was found between the ApoA1 level and TNFα-308 polymorphism, because in patients with GG haplotype the adverse effect of low ApoA1 level on survival was more prevalent. Conclusions: Lower ApoA1 levels were strongly associated with adverse outcome in CHF patients in a TNFα-308 polymorphism dependent manner. These observations support the complex involvement of malnutrition and inflammation in the pathogenesis of CHF.",
keywords = "Apolipoprotein A1 (ApoA1), Cholesterol paradox, Chronic heart failure (CHF), TNFα-308 G/A promoter polymorphisms, Tumor necrosis factor alpha (TNFα)",
author = "T{\'i}mea Gombos and Zsolt F{\"o}rh{\'e}cz and Zolt{\'a}n Pozsonyi and L{\'i}via J{\'a}noskuti and Z. Proh{\'a}szka and I. Kar{\'a}di",
year = "2015",
month = "12",
day = "10",
doi = "10.1016/j.cardfail.2016.06.004",
language = "English",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",

}

TY - JOUR

T1 - Long-Term Survival and Apolipoprotein A1 Level in Chronic Heart Failure

T2 - Interaction With Tumor Necrosis Factor α-308 G/A Polymorphism

AU - Gombos, Tímea

AU - Förhécz, Zsolt

AU - Pozsonyi, Zoltán

AU - Jánoskuti, Lívia

AU - Prohászka, Z.

AU - Karádi, I.

PY - 2015/12/10

Y1 - 2015/12/10

N2 - Background: Apolipoprotein A1 (ApoA1), a major constituent of high-density lipoprotein (HDL), has antiinflammatory and antioxidative properties and plays a prognostic role in chronic heart failure (CHF). Despite increased tumor necrosis factor α (TNFα) levels being linked to worse outcome of HF, the results are ambiguous about the association of functionally active 308 promoter polymorphism of the TNFα gene. The aims of our study were to investigate the association of ApoA1 and TNFα levels with mortality and to evaluate potential interaction between these factors and TNFα-308 polymorphism. Methods: Together with several parameters ApoA1, TNFα levels and TNFα-308 polymorphism were determined in a cohort of 195 patients with CHF who were followed for 5 years. Results: Low ApoA1 and high TNFα levels were associated with more severe disease, and ApoA1 showed the strongest relationship with HDL, total cholesterol, C-reactive protein, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). TNFα-308 A carriers had significantly higher ApoA1 levels than wild-type (GG) patients (1.41 ± 0.268 vs 1.29 ± 0.324 g/L; . P = .007), whereas levels of TNFα were the same in these groups. Decreased ApoA1 levels were significant predictors of 5-year mortality (NT-proBNP-adjusted HR for 1 decile decrease in ApoA1 level was 1.10 (P = .011). Interaction was found between the ApoA1 level and TNFα-308 polymorphism, because in patients with GG haplotype the adverse effect of low ApoA1 level on survival was more prevalent. Conclusions: Lower ApoA1 levels were strongly associated with adverse outcome in CHF patients in a TNFα-308 polymorphism dependent manner. These observations support the complex involvement of malnutrition and inflammation in the pathogenesis of CHF.

AB - Background: Apolipoprotein A1 (ApoA1), a major constituent of high-density lipoprotein (HDL), has antiinflammatory and antioxidative properties and plays a prognostic role in chronic heart failure (CHF). Despite increased tumor necrosis factor α (TNFα) levels being linked to worse outcome of HF, the results are ambiguous about the association of functionally active 308 promoter polymorphism of the TNFα gene. The aims of our study were to investigate the association of ApoA1 and TNFα levels with mortality and to evaluate potential interaction between these factors and TNFα-308 polymorphism. Methods: Together with several parameters ApoA1, TNFα levels and TNFα-308 polymorphism were determined in a cohort of 195 patients with CHF who were followed for 5 years. Results: Low ApoA1 and high TNFα levels were associated with more severe disease, and ApoA1 showed the strongest relationship with HDL, total cholesterol, C-reactive protein, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). TNFα-308 A carriers had significantly higher ApoA1 levels than wild-type (GG) patients (1.41 ± 0.268 vs 1.29 ± 0.324 g/L; . P = .007), whereas levels of TNFα were the same in these groups. Decreased ApoA1 levels were significant predictors of 5-year mortality (NT-proBNP-adjusted HR for 1 decile decrease in ApoA1 level was 1.10 (P = .011). Interaction was found between the ApoA1 level and TNFα-308 polymorphism, because in patients with GG haplotype the adverse effect of low ApoA1 level on survival was more prevalent. Conclusions: Lower ApoA1 levels were strongly associated with adverse outcome in CHF patients in a TNFα-308 polymorphism dependent manner. These observations support the complex involvement of malnutrition and inflammation in the pathogenesis of CHF.

KW - Apolipoprotein A1 (ApoA1)

KW - Cholesterol paradox

KW - Chronic heart failure (CHF)

KW - TNFα-308 G/A promoter polymorphisms

KW - Tumor necrosis factor alpha (TNFα)

UR - http://www.scopus.com/inward/record.url?scp=84979527829&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979527829&partnerID=8YFLogxK

U2 - 10.1016/j.cardfail.2016.06.004

DO - 10.1016/j.cardfail.2016.06.004

M3 - Article

C2 - 27317841

AN - SCOPUS:84979527829

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

ER -